Riverstone HoldingsSGX:AP4 +2.41%63 ROE % is 14.73% as of Dec. 2025, which is 21% below its 10-year median of 18.71. GuruFocus rates SGX:AP4 with a GF Score™ of 63/100 and a GF Value™ of S$0.86 (Fairly Valued). The stock has 5 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Riverstone Holdings ranks better than 83.19% on this metric.
The historical rank and industry rank for Riverstone Holdings's ROE % or its related term are showing as below:
SGX:AP4'
s ROE % Range Over the Past 10 Years
Min: 12.02 Med: 18.71 Max: 76.42
Current: 13.62
During the past 13 years, Riverstone Holdings's highest ROE % was 76.42%. The lowest was 12.02%. And the median was 18.71%.
SGX:AP4's ROE % is ranked better than 83.19% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs SGX:AP4: 13.62
Riverstone Holdings (SGX:AP4) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Riverstone Holdings ROE % Related Terms
Riverstone Holdings ROE % Historical Data
* Premium members only.
The historical data trend for Riverstone Holdings's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Riverstone Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Riverstone Holdings ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Riverstone Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where Riverstone Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Riverstone Holdings (SGX:AP4) has a ROE % of 14.73% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Riverstone Holdings and its competitors. This is 21% below median its historical median of 18.71. Over the past decade, Riverstone Holdings' ROE % has ranged from 12.02 to 76.42. According to the industry distribution chart, Riverstone Holdings ranks #134 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 16.8%.
Is Riverstone Holdings' ROE % too high?
Riverstone Holdings' current ROE % of 14.73% is 21% below median its 10-year median of 18.71. Over the past 10 years, this metric has ranged from a low of 12.02 to a high of 76.42. The Medical Devices & Instruments industry median ROE % is 2.40. Riverstone Holdings' value of 14.73% is 513.8% above this industry median. Based on the distribution chart, Riverstone Holdings ranks #134 out of 797 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Riverstone Holdings has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Riverstone Holdings' ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Riverstone Holdings ranks #134 out of 797 companies for ROE %. This places Riverstone Holdings in the top 17% of its industry — outperforming the majority of peers. The industry median ROE % is 2.40. Riverstone Holdings' value of 14.73% is 513.8% above this benchmark. Historically, Riverstone Holdings' own ROE % has ranged from 12.02 to 76.42 over the past decade. While the company's 10-year median is 18.71 vs. the industry median of 2.40, Riverstone Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Riverstone Holdings's current ROE % of 14.73% is 513.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Riverstone Holdings and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Riverstone Holdings's current ROE % is 14.73%, which is 21% below median its own 10-year median of 18.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Riverstone Holdings stock overvalued right now?
Based on GuruFocus' analysis, Riverstone Holdings (SGX:AP4) is currently considered Fairly Valued. The stock's GF Value™ is S$0.86, compared to a current price of S$0.85 — trading 1.2% below its estimated fair value. The current ROE % is 14.73%, which is 21% below median its 10-year median of 18.71 and 513.8% above the Medical Devices & Instruments industry median of 2.40. Riverstone Holdings' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Riverstone Holdings (SGX:AP4), the current ROE % is 14.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Riverstone Holdings (SGX:AP4) Overvalued in 2026?
Based on GuruFocus' analysis, Riverstone Holdings stock appears to be undervalued.
The current stock price of S$0.85 is trading 1.2% below its estimated GF Value™ of S$0.86.
GuruFocus considers Riverstone Holdings to be Fairly Valued.
Key valuation signals for SGX:AP4:
ROE %: 14.73% (21% below median its 10-year median of 18.71)
GF Value™: S$0.86 vs. price of S$0.85 (1.2% below fair value)
Industry Position: 513.8% above the Medical Devices & Instruments median (#134 of 797)
No single metric tells the full story. See the SGX:AP4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Riverstone Holdings Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the manufacture and sales of gloves and non-glove consumables such as finger cots, static shielding bags, face masks, wipers, and packaging materials. The group's products are widely qualified and used in the Hard Disk Drive, and semiconductor industries. It operates in three segments based on its geography: Malaysia, Thailand, China, Singapore, and Others, of which the majority of its revenue comes from Malaysia.
63GF Score
Get the complete analysis for SGX:AP4
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:AP4 has been successfully added to your 
